These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 5132580)

  • 1. Effects of L-DOPA treatment on indole metabolism in Parkinson's disease.
    Brune GG; Pflughaupt KW
    Experientia; 1971 May; 27(5):516. PubMed ID: 5132580
    [No Abstract]   [Full Text] [Related]  

  • 2. Indoleamine metabolism in affective disorders: excretion of tryptamine, indoleacetic acid and 5-hydroxy-indoleacetic acid in depressive states.
    McNamee HB; Moody JP; Naylor GJ
    J Psychosom Res; 1972 Feb; 16(1):63-70. PubMed ID: 5058989
    [No Abstract]   [Full Text] [Related]  

  • 3. Excretion patterns of tryptamine, indoleacetic acid, and 5-hydroxyindoleacetic acid, and their correlation with mental changes in schizophrenic patients under medication with alpha-methyldopa.
    Herkert EE; Keup W
    Psychopharmacologia; 1969; 15(1):48-59. PubMed ID: 5367444
    [No Abstract]   [Full Text] [Related]  

  • 4. Metabolism of L-dihydroxyphenylalanine by patients with Parkinson's disease.
    Tyce GM; Muenter MD; Owen CA
    Mayo Clin Proc; 1970 Sep; 45(9):645-56. PubMed ID: 5311767
    [No Abstract]   [Full Text] [Related]  

  • 5. The effect of L-dopa on monoamine metabolites in Parkinson's disease.
    van Woert MH; Bowers MB
    Experientia; 1970; 26(2):161-3. PubMed ID: 5308739
    [No Abstract]   [Full Text] [Related]  

  • 6. 5-Hydroxyindoleacetic acid in cerebrospinal fluid of patients with Parkinson's syndrome treated with L dopa.
    Johansson B; Roos BE
    Eur J Clin Pharmacol; 1971 Sep; 3(4):232-5. PubMed ID: 5151306
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of L-dopa therapy on urinary p-tyramine excretion and EEG changes in Parkinson's disease.
    Boulton AA; Marjerrison GL
    Nature; 1972 Mar; 236(5341):76-8. PubMed ID: 4553458
    [No Abstract]   [Full Text] [Related]  

  • 8. Dopaminergic nervous transmission in Parkinson's disease.
    Rinne UK; Sonninen V; Riekkinen P; Laaksonen H
    Med Biol; 1974 Jun; 52(3):208-17. PubMed ID: 4371255
    [No Abstract]   [Full Text] [Related]  

  • 9. EEG and urinary non-catecholic amine changes during L-dopa therapy of Parkinson's disease.
    Marjerrison G; Boulton AA; Rajput AH
    Dis Nerv Syst; 1972 Mar; 33(3):164-9. PubMed ID: 5022451
    [No Abstract]   [Full Text] [Related]  

  • 10. Tryptophan malabsorption in levodopa-treated parkinsonian patients. Effect of tryptophan on mental disturbances.
    Lehmann J
    Acta Med Scand; 1973; 194(3):181-9. PubMed ID: 4746526
    [No Abstract]   [Full Text] [Related]  

  • 11. Predictive value of the probenecid test for the effect of L-DOPA therapy in Parkinson's disease.
    Lakke JP; Korf J; Van Praag HM; Schut T
    Nat New Biol; 1972 Apr; 236(68):208-9. PubMed ID: 4553111
    [No Abstract]   [Full Text] [Related]  

  • 12. Analysis for indole compounds in urine by high-performance liquid chromatography with fluorometric detection.
    Graffeo AP; Karger BL
    Clin Chem; 1976 Feb; 22(2):184-7. PubMed ID: 2390
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On the relationship between L-DOPA therapy and CSF monoamine metabolites in Parkinson's disease.
    Casati C; Agnoli A; Jori A; Dolfini E
    Z Neurol; 1973 Apr; 204(2):149-54. PubMed ID: 4121468
    [No Abstract]   [Full Text] [Related]  

  • 14. 5-Hydroxytryptamine and tryptamine pathways in scleroderma.
    Stachow A; Jablonska S; Skiendzielewska A
    Br J Dermatol; 1977 Aug; 97(2):147-54. PubMed ID: 911677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Urinary indoleamines in Tourette syndrome patients with obsessive-compulsive characteristics.
    Bornstein RA; Baker GB
    Psychiatry Res; 1992 Mar; 41(3):267-74. PubMed ID: 1375759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Central monoamine metabolism in Parkinson's disease.
    Chase TN; Ng LK
    Arch Neurol; 1972 Dec; 27(6):486-91. PubMed ID: 5083866
    [No Abstract]   [Full Text] [Related]  

  • 17. Homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5HIAA) during L-dopa therapy of Parkinson's disease.
    van Woert MH; Bowers MB
    Neurology; 1970 Apr; 20(4):377. PubMed ID: 5534981
    [No Abstract]   [Full Text] [Related]  

  • 18. Monoamine metabolism and depression in Parkinson patients.
    Puite JK; Schut T; van Praag HM; Lakke JP
    Psychiatr Neurol Neurochir; 1973; 76(1):61-70. PubMed ID: 4699106
    [No Abstract]   [Full Text] [Related]  

  • 19. L-dopa in Parkinson's disease. A report on 95 cases and review of the literature.
    Lewis I
    J Med Assoc State Ala; 1971 May; 40(11):709-18. PubMed ID: 5573008
    [No Abstract]   [Full Text] [Related]  

  • 20. Analysis of urinary excretion patterns of bioactive amines and their metabolites in normal control subjects.
    Hopkinson G; Baker GB; Douglass AB; McKim HR; Dewhurst WG
    Prog Neuropsychopharmacol Biol Psychiatry; 1982; 6(4-6):495-8. PubMed ID: 6187046
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.